Solid Biosciences Inc.

Solid Biosciences Inc. is a biotechnology company focused on developing therapies for neuromuscular and cardiac diseases. Its lead product candidate is SGT-003, a gene therapy currently in phase 1/2 clinical trials for Duchenne muscular dystrophy (DMD). The company also has SGT-212 for Friedreich's ataxia in phase 1b, and several preclinical programs including SGT-501 for catecholaminergic polymorphic ventricular tachycardia, SGT-601 for TNNT2-mediated dilated cardiomyopathy, and SGT-401 for BAG3-mediated dilated cardiomyopathy. Additionally, it is developing platform technologies such as capsid libraries, genetic regulators (promoters, UTRs, introns), immunomodulation technologies, and dual gene expression for packaging multiple transgenes into one capsid.

Solid Biosciences Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol SLDB. Its shares are traded in US Dollars (USD), as the company is based in the United States. The exchange is a major US stock exchange that hosts many biotechnology and healthcare companies.

Solid Biosciences operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies use biological processes and living organisms to develop products and therapies, often focusing on genetic engineering and molecular biology. Solid Biosciences' work in gene therapies for neuromuscular and cardiac diseases places it firmly in this innovative and research-intensive field.

Solid Biosciences is headquartered in Charlestown, Massachusetts, United States. The company primarily serves the US market, as indicated by its focus on US-based clinical trials and regulatory pathways. While its therapies target global diseases like Duchenne muscular dystrophy and Friedreich's ataxia, its operations and collaborations are centered in the United States, with partnerships including Ultragenyx Pharmaceutical Inc. and academic institutions such as the University of Washington and University of Florida.

Solid Biosciences has a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., as well as license agreements with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. The company is developing several platform technologies, including capsid libraries for improved gene delivery, genetic regulators like promoters and UTRs to control gene expression, immunomodulation technologies to reduce immune responses, and dual gene expression technology that allows packaging multiple transgenes into one capsid. These platforms aim to enhance the efficacy and safety of its gene therapy candidates.